Ben
Goldacre's 'Bad Pharma' proposes transparency as the cure for the shocking
ailments of the pharmaceutical industry
 |
| Please read instructions carefully |
Ben
Goldacre's new book, Bad Pharma, is awful. Dreadful. Stunning. You should read
it.
If you
think that's too melodramatic an opening for a book review, that's probably
because you haven't read the book yet.
You should
read it because behind the anodyne cover lurks a tale of horrific fascination
that affects us all. Bad Pharma is the story of the ways in which the
pharmaceutical industry, with the help of regulators, doctors and academics,
seeks to pervert and obfuscate the research done to test new medicines. It may
be rather technical in content, but from more or less page one Goldacre is
clear about who are the primary victims in his sorry story: all of us. Happily,
we might also be part of the solution.
It seems
hard to credit that the situation could be so bad. The scale of the problem is
rendered starkly in the preface:
"Drugs
are tested by the people who manufacture them, in poorly designed trials, on
hopelessly small numbers of weird, unrepresentative patients, and analysed
using techniques which are flawed by design, in such a way that they exaggerate
the benefits of treatments. Unsurprisingly, these trials tend to produce
results that favour the manufacturer. When trials produce results that
companies don't like, they are perfectly entitled to hide them from doctors and
patients, so we only ever see a distorted picture of any drug's true
effects."
These
claims may be startling to some but they have not been made airily. Many of the
problems that Goldacre describes have been researched and identified by others,
and he proceeds to take a full 373 pages to lay out the evidence for his case,
in chapters that explain how trials are designed to maximise the apparent
benefits of new drugs, how negative results are hidden, how regulators collude
with the industry in hiding data on efficacy and safety from doctors and how
the industry bankrolls doctors, academics and medical journals to ensure the
most favourable presentation of its products.
The book
touches on several issues that Goldacre has raised in his Guardian column over
the years but the whole is so much greater than the sum of these earlier parts.
While his trademark conversational style makes it a relatively easy read,
there's no doubting this is a heavier, denser book than his previous offering,
Bad Science. The emphasis on research into the conduct and reporting of
clinical trials may cost the book some anecdotal colour, but I think this was
the right editorial choice given the seriousness and complexity of the subject
matter.
David Colquhoun, Richard Smith (former British Medical Journal Editor), Alice Bell
(for the New Left Project), and Michael Rawlins of NICE, among others, have
already reviewed the book in some depth. While some interesting points of
criticism were raised, all generally applauded the forensic attention that
Goldacre has brought to the drugs business. The accuracy of his aim is
underscored by the weakness of the riposte from Stephen Whitehead, CEO of the
Association of the British Pharmaceutical Industry.
I don't
propose to do a comprehensive assessment here — please take a look at the
reviews mentioned above to get a good idea of its structure and content. It's
not all bad of course, as Goldacre takes some trouble to point out. There are
plenty of good people in the pharmaceutical industry who are working hard on difficult problems — I should note, for example, that I am only able to write
this piece because my 'flu symptoms are being held in check by paracetamol and
ibuprofen — but it's impossible to walk away from Bad Pharma without the stink
of sickness in your nostrils.
Rather, I
want to focus on the fact that Goldacre's diagnosis of the ailments of the
drugs business is accompanied by specific suggestions of how to its problems
might be cured. In almost every case transparency — or access to information —
is the key.
Bad
Pharma's most important message is that full disclosure is needed to prevent us
being duped. We need to know the results of all clinical trials so that
evidence of efficacy is not distorted; we need to know how much drug reps are
spending on doctors in promoting their products (often in the guise of
continuing medical education); we need to know the origin and total value of
all the benefits each doctor receives from Pharma; we need to know when
academics have been induced to add a veneer of credibility to research papers
written by unnamed industry workers by adding their names as co-authors.
The
solutions are mechanistically simple but will likely encounter resistance from
many sides. I suspect there is a culture of dependency that the medical and
academic establishments will have to overcome. No-one is saying it's going to
be easy but until the problems are fixed, patients are suffering needlessly.
The book
may be shocking but I retain a sense of optimism. Goldacre's message on
complete transparency resonates with the new enthusiasm for openness that seems
to be pervading government and academia, driven by the ready access to
information made possible by the world-wide web. Indeed it already seems to be
making waves in parliament.
Goldacre,
ever the nerd, is at his most persuasive on the power of the internet to
facilitate simple trials on existing, similar drugs which have not yet been
properly compared when used in the real world. These could be run directly from
GP consultation rooms and as such have the potential to engage many more people
in clinical trials and, just as importantly, in conversations about how the
drugs prescribed for their ailments are developed and tested. This is my
favourite paragraph of the whole book (p236):
"I
think we need a cultural shift in the way we all, as patients, view our
reciprocal relationship with research in medicine. We only know what works
because of trials, and we all profit from the participation of patients before
us in these trials; but many of us seem to have forgotten this. By remembering,
we could create a social contract whereby everyone expects their health service
to be constantly conducting trials, simple A/B tests, comparing treatments
against each other to see which is the best, or even the cheapest, if they're
both equally effective. A doctor failing to take part in such tests could be
regarded as an oddity who is harming future patients. It could be obvious to
all patients than participating in these files is a normal reflection of the
need to produce better evidence to improve medical treatments, for themselves
in the future, and for the others in the community with whom they share their
medical system."
Of course,
the results of any such trial should be published in an open access journal to
ensure that they are available to all possible trial participants. By which I
mean: everybody.
It may be
too late to buy a copy of Bad Pharma in time for Christmas, but it could be
just the thing for a new year's revolution.
Full Disclosure:
Ben Goldacre, whom I know slightly, kindly arranged for his publisher to send
me a free copy of Bad Pharma.
Stephen
Curry is a Professor of Structural Biology. Follow him on Twitter as
@Stephen_Curry.
